GlassScriptPhysician profile
Dana Kirby
NPI 1730282781
$3,239.74
in general payments reported to CMS, 2019-2025
31 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $512 · 2021: $648 · 2022: $452 · 2023: $532 · 2024: $416 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,010.00 | 2021-2025 | |
| Glaxosmithkline, LLC. | $313.05 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $308.47 | 2020-2025 | Freestyle Libre 3, Gallant |
| Lilly USA, LLC | $239.91 | 2020-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $163.54 | 2020-2022 | |
| Allergan, INC. | $151.85 | 2019-2021 | |
| Pfizer INC. | $130.39 | 2019-2025 | |
| Novo Nordisk INC | $128.69 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.47 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $99.76 | 2019-2023 | Xarelto |
| Dexcom, INC. | $74.48 | 2022-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $67.81 | 2020-2024 | Contrave |
| Tris Pharma INC | $45.03 | 2023 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $38.67 | 2020 | |
| Novartis Pharmaceuticals Corporation | $37.23 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $36.26 | 2020 | |
| Astellas Pharma US INC | $35.72 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $29.27 | 2021 | |
| Amgen INC. | $28.07 | 2021-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $23.19 | 2025 | The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $20.02 | 2023 | Inspire |
| Ibsa Pharma INC. | $18.14 | 2024 | Tirosint, Licart |
| Supernus Pharmaceuticals, INC. | $17.68 | 2021 | |
| Avvisto Therapeutics, LLC | $17.63 | 2025 | Cycloset |
| Bausch Health US, LLC | $16.33 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.80 | 2024 | Cycloset |
| Kowa Pharmaceuticals America, INC. | $15.10 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $14.51 | 2022 | |
| Esperion Therapeutics, INC. | $14.41 | 2020 | |
| Phadia US INC. | $12.85 | 2019 | |
| Si-Bone, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Kirby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.